BioRegenx, Inc. (BRGX)
OTCMKTS · Delayed Price · Currency is USD
0.0080
-0.0010 (-11.11%)
May 13, 2026, 12:24 PM EST

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Medical Testing, Diagnostic and Nutraceutical Company
1.85M2.34M3.41M42.16K3.99M
Medical Testing, Diagnostic and Nutraceutical Company Growth
-20.75%-31.40%7991.78%-98.94%-48.79%
Total
1.85M2.34M3.41M42.16K3.99M
Total Growth
-20.75%-31.40%7991.78%-98.94%-48.79%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
United States
1.85M2.34M3.41M42.16K3.99M
United States Growth
-20.75%-31.40%7991.78%-98.94%-48.79%
Total
1.85M2.34M3.41M42.16K3.99M
Total Growth
-20.75%-31.40%7991.78%-98.94%-48.79%
Source: S&P Global Market Intelligence.